Mon, 09/05/2016 - 14:09
The Scottish Medicines Consortium Committee has today announced it has accepted the use of bevacizumab (Avastin) for advanced cervical cancer by NHS Scotland, this followed a consultation which Jo’s Cervical Cancer Trust responded to.
Robert Music, Chief Executive of Jo’s Cervical Cancer Trust said: “Avastin has been shown to increase average survival by approximately four months and we are delighted by this announcement which will offer women in Scotland with an incurable cervical cancer diagnosis invaluable extra time.
"We want to ensure that every woman in the UK facing a terminal cancer diagnosis has access to drugs which could have a huge impact on their quality of life in their final months.”
Avastin was reinstated on to the Cancer Drugs Fund in England in November 2015 meaning that women in England and Scotland can now access this potentially life prolonging drug. Women living in Wales or Northern Ireland can find out from their specialist if it is available to them.